Minor
ES102 in Combination With Toripalimab · Advanced Non-small Cell Lung Cancer
Enrollment closed, study ongoing
Also in this update: Final enrollment: 30 participants (planned 40)
Elpiscience (Suzhou) Biopharma, Ltd.Phase 2 NCT06623136 Registry history of NCT06623136 on ClinicalTrials.gov (opens the registry)